News

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Novavax stock has delivered a sharp 5 year decline alongside a recent rebound, and the broader valuation checks now point to a mixed picture rather than a clear bargain or clear overvaluation at the current price. The share price return over 5 years is down 96.3%, which signals that long term holders have absorbed very heavy losses despite the recent bounce. Future demand for Novavax products and the company’s ability to convert that demand into steady cash flow can support the equity story,...

By Avinash P and Purvi Agarwal Aug 19 (Reuters) - The main U.S. stock indexes were on track to open higher on Wednesday after a tech-led selloff in the previous session as investors assessed fresh

ADMA Biologics matches earnings estimates, misses on revenues and maintains its 2026 outlook as strong Asceniv growth offsets continued pressure on Bivigam.

Novavax stock has staged a modest recovery in the past year, yet the longer record is still heavily negative and current market multiples screen as expensive for many investors looking at valuation. With the company scoring in the middle of the range on broader checks, the picture is more nuanced than a simple cheap or expensive label. Over the past 5 years, Novavax has delivered a decline of about 96.8%, which keeps longer term holders deeply under water despite shorter term...

In the most recent trading session, Novavax (NVAX) closed at $7.37, indicating a -1.6% shift from the previous trading day.

Novavax (NVAX) reached $7.88 at the closing of the latest trading day, reflecting a -4.02% change compared to its last close.

Novavax (NVAX) has been removed from several Russell growth and small cap benchmarks, a shift that can influence index fund ownership and prompt investors to reassess how the stock fits in their portfolios. See our latest analysis for Novavax. The index removals come after a mixed run for Novavax, with the share price at $9.40 and a 30 day share price return of 8.42%, a 90 day share price return of 15.76%, and a year to date share price return of 31.84%. This is set against a 1 year total...

Novavax (NasdaqGS:NVAX) has been removed from multiple major Russell growth indices. The changes follow the latest Russell index review and rebalancing cycle. Exclusion affects its presence in certain growth focused benchmarks tracked by passive funds. Novavax focuses on protein based vaccines, including its Covid 19 product and other pipeline candidates. Index changes arrive as vaccine makers continue to adjust to post pandemic demand patterns, shifting procurement models, and evolving...

Novavax (NVAX) concluded the recent trading session at $9.35, signifying a -1.16% move from its prior day's close.

In the closing of the recent trading day, Novavax (NVAX) stood at $8.9, denoting a -1.17% move from the preceding trading day.

Novavax (NVAX) closed the most recent trading day at $9.13, moving 3.89% from the previous trading session.

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

The U.S. health department said one passenger on a repatriation flight has tested mildly positive for the virus, while another is currently experiencing mild symptoms.